Drugs / FluBHPVE6E7
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06589609 | Aug 2024 → Nov 2027 expected | oropharynx squamous cell carcinoma | BlueSky Immunotherapies GmbH | Recruiting | No outcome recorded |
| Phase 1 | NCT05829629 | Sep 2023 → Sep 2025 overdue | cervical carcinoma, human papilloma virus infection | BlueSky Immunotherapies GmbH | Recruiting | No outcome recorded |
| Phase 1 | NCT04490512 | Dec 2020 → Mar 2023 | human papilloma virus infection | BlueSky Immunotherapies GmbH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FluBHPVE6E7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04490512 ↗ |
| Modality | Vaccine | “systemic immune responses to immunisations with FluBHPVE6E7” NCT04490512 ↗ |
| Route | Intramuscular | “Multiple subcutaneous, intradermal or intramuscular administrations” NCT04490512 ↗ |
| Route | Subcutaneous | “Multiple subcutaneous, intradermal or intramuscular administrations” NCT04490512 ↗ |